T. Rowe Price Associates’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $237K | Buy |
76,523
+11,002
| +17% | +$34.1K | ﹤0.01% | 2631 |
|
|
2025
Q1 | $229K | Buy |
65,521
+9,069
| +16% | +$31.7K | ﹤0.01% | 2574 |
|
|
2024
Q4 | $185K | Buy |
56,452
+8,648
| +18% | +$28.3K | ﹤0.01% | 2702 |
|
|
2024
Q3 | $185K | Buy |
47,804
+3,278
| +7% | +$12.7K | ﹤0.01% | 2675 |
|
|
2024
Q2 | $138K | Buy |
44,526
+8,138
| +22% | +$25.2K | ﹤0.01% | 2687 |
|
|
2024
Q1 | $94K | Buy |
36,388
+6,649
| +22% | +$17.2K | ﹤0.01% | 2794 |
|
|
2023
Q4 | $75K | Buy |
29,739
+3,004
| +11% | +$7.58K | ﹤0.01% | 2754 |
|
|
2023
Q3 | $55K | Buy |
26,735
+1,106
| +4% | +$2.28K | ﹤0.01% | 2763 |
|
|
2023
Q2 | $59K | Buy |
25,629
+4,134
| +19% | +$9.52K | ﹤0.01% | 2778 |
|
|
2023
Q1 | $66K | Buy |
21,495
+1,446
| +7% | +$4.44K | ﹤0.01% | 2749 |
|
|
2022
Q4 | $47K | Buy |
20,049
+1,974
| +11% | +$4.63K | ﹤0.01% | 2818 |
|
|
2022
Q3 | $35K | Buy |
18,075
+7,992
| +79% | +$15.5K | ﹤0.01% | 2869 |
|
|
2022
Q2 | $27K | Buy |
+10,083
| New | +$27K | ﹤0.01% | 2908 |
|
|
2018
Q4 | – | Sell |
-497,328
| Closed | -$4.7M | – | 2545 |
|
|
2018
Q3 | $4.7M | Buy |
+497,328
| New | +$4.7M | ﹤0.01% | 1463 |
|